EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-effectiveness analysis of ribociclib versus palbociclib as a first line theraphy in HR+/HER2- advanced breast cancer: evidence from the Chilean public health system

C Balmaceda, N Armijo, M Espinoza

Expert Review of Pharmacoeconomics & Outcomes Research · 2026

DOI: 10.1080/14737167.2025.2593350 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2026. Verfasst von C Balmaceda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Epsilon Research, Santiago, Chile. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Novartis and commissioned to Epsilon Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ribociclib plus letrozole significantly improves survival in HR+/HER2- advanced-stage or metastatic postmenopausal breast cancer (BC) patients. AIM: To evaluate the cost-effectiveness of first-line ribociclib plus letrozole versus palbociclib plus letrozole for HR+/HER2- advanced BC in the Chilean public healthcare system. METHODS: A partitioned survival model with a 1-month cycle and 40-year horizon was utilized. Data were drawn from PALOMA-2 and MONALEESA-2 trials. Utility values were sourced from trial data and literature. Costs included drug acquisition, disease monitoring, subsequent therapies, and adverse events. Deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and scenario analyses with varying clinical efficacy estimates were conducted to address uncertainty. RESULTS: Ribociclib plus letrozole consistently dominated palbociclib plus letrozole, showing better effectiveness at lower costs. In the base case, ribociclib saved $5,724 with an additional 0.506 QALYs. Scenario 1 showed savings of $4,942 and 0.398 QALYs, while Scenario 2 indicated $9,830 saved with 1.282 QALYs gained. PSA confirmed a 100% probability of ribociclib being cost-effective at a willingness-to-pay threshold of 1 GDP per capita. CONCLUSION: Ribociclib plus letrozole is cost-saving and cost-effective compared to palbociclib plus letrozole for the first-line treatment of postmenopausal women with HR+/HER2- advanced BC in Chile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansCost-Benefit AnalysisFemaleChileAminopyridinesLetrozolePiperazinesPyridinesQuality-Adjusted Life YearsPurinesErb-b2 Receptor Tyrosine KinasesPostmenopauseSurvival AnalysisPublic HealthSurvival RateCost-Effectiveness Analysis

Stichwörter der Autor:innen

CDK 4/6 inhibitorsHR+/HER2-advanced breast cancercost-effectivenessletrozolepalbociclibribociclib

Substanzen

AminopyridinesLetrozolePiperazinesPyridinesPurinesErb-b2 Receptor Tyrosine KinasesribociclibpalbociclibERBB2 protein, human

Autor:innen und Institutionen

  • Epsilon Research, Santiago, Chile.
  • School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.

Förderung

  • Novartis and commissioned to Epsilon Research

Zitieren

APA

Balmaceda, C., Armijo, N., & Espinoza, M. (2026). Cost-effectiveness analysis of ribociclib versus palbociclib as a first line theraphy in HR+/HER2- advanced breast cancer: evidence from the Chilean public health system. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2593350

Vancouver

Balmaceda C, Armijo N, Espinoza M. Cost-effectiveness analysis of ribociclib versus palbociclib as a first line theraphy in HR+/HER2- advanced breast cancer: evidence from the Chilean public health system. Expert Review of Pharmacoeconomics & Outcomes Research. 2026. doi:10.1080/14737167.2025.2593350

BibTeX
@article{Balmaceda2026,
  author = {Balmaceda, C and Armijo, N and Espinoza, M},
  title = {Cost-effectiveness analysis of ribociclib versus palbociclib as a first line theraphy in HR+/HER2- advanced breast cancer: evidence from the Chilean public health system},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2026},
  doi = {10.1080/14737167.2025.2593350}
}
Kostenlos starten →